1. Home
  2. GASS vs LXEO Comparison

GASS vs LXEO Comparison

Compare GASS & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GASS

StealthGas Inc.

N/A

Current Price

$8.14

Market Cap

319.4M

ML Signal

N/A

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

N/A

Current Price

$3.13

Market Cap

348.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GASS
LXEO
Founded
2004
2017
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
319.4M
348.7M
IPO Year
2005
2023

Fundamental Metrics

Financial Performance
Metric
GASS
LXEO
Price
$8.14
$3.13
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $20.30
AVG Volume (30 Days)
93.5K
★ 1.5M
Earning Date
11-24-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.81
EPS
★ N/A
N/A
Revenue
N/A
★ $654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.00
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.55
$2.55
52 Week High
$10.55
$10.99

Technical Indicators

Market Signals
Indicator
GASS
LXEO
Relative Strength Index (RSI) 31.81 49.56
Support Level $7.69 $2.98
Resistance Level $8.24 $3.68
Average True Range (ATR) 0.19 0.23
MACD -0.04 0.08
Stochastic Oscillator 8.58 97.01

Price Performance

Historical Comparison
GASS
LXEO

About GASS StealthGas Inc.

StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: